What Is Sivextro Used For?
Sivextro (tedizolid phosphate) treats acute bacterial skin and skin structure infections (ABSSSI), such as cellulitis, wound infections, and major abscesses caused by susceptible bacteria like Staphylococcus aureus (including MRSA) and Streptococcus pyogenes.[1]
How Does It Work Against Infections?
Sivextro is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, stopping growth of Gram-positive bacteria. It's given intravenously or orally once daily for 6 days, with high bioavailability allowing quick IV-to-oral switch.[1][2]
What Infections Does It Target Specifically?
Approved for ABSSSI only, not broader infections like pneumonia, urinary tract infections, or Gram-negative bacterial issues. It's not for viral, fungal, or uncomplicated skin infections.[1]
Who Makes Sivextro and When Did It Launch?
Merck & Co. developed and markets Sivextro. FDA approved it in June 2014 for adults; expanded pediatric approval came in 2022 for ages 12+.[1][2]
Common Side Effects and Patient Concerns
Nausea (4-8%), headache, diarrhea, and vomiting occur most often. Rare risks include Clostridium difficile-associated diarrhea, myelosuppression, or serotonin syndrome with certain antidepressants. Monitor liver function; avoid in kids under 12.[1]
How Does Sivextro Compare to Other Antibiotics?
Shorter 6-day course vs. vancomycin's 7-14 days or linezolid's similar dosing. Better tolerability than linezolid (less nausea, no daily MAO inhibition warnings). Active against MRSA like daptomycin but oral option sets it apart.[2]
Patent Status and Generic Availability
U.S. patents on Sivextro expire around 2032-2036, per DrugPatentWatch.com data; no generics approved yet.[3] Exclusivity ends post-2026, but litigation could delay biosimilars or equivalents.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205435s012lbl.pdf
[2] Merck Product Info: https://www.sivextro.com/
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/SIVEXTRO